Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Gareth I Owen, Miguel Cordova-Delgado, Bernabé I Bustos, Leslie C Cerpa, Pamela Gonzalez, Sebastián Morales-Pison, Benjamín Garcia-Bloj, Marcelo Garrido, Juan Francisco Miquel, Luis A Quiñones
BACKGROUND: Pharmacogenomic knowledge as a biomarker for cancer care has transformed clinical practice, however, as current guidelines are primarily derived from Eurocentric populations, this limits their application in Latin America, particularly among Hispanic or Latino groups. Despite advancements, systemic chemotherapy still poses challenges in drug toxicity and suboptimal response. This study explores pharmacogenetic markers related to anticancer drugs in a Chilean cohort, filling a gap in Latin American research...
April 19, 2024: Pharmaceutics
#2
REVIEW
Katarzyna Stasik, Rafał Filip
Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. In addition, there may be a link between the use of thiopurines or anti-tumor necrosis factor drugs (anti-TNF) and these pathologies. The treatment of patients with Crohn's disease who have previously been diagnosed with lymphoma is a challenge for gastroenterologists. In this report, we examine important clinical issues related to the treatment of patients with inflammatory bowel disease with active lymphoma, as well as of patients with hematological cancer history...
April 11, 2024: International Journal of Molecular Sciences
#3
REVIEW
Morris Gordon
Surgery is a vital pillar in the management of Crohn's disease and medical options for prevention of recurrence after surgery are a key consideration. The main classes of effective induction therapies have very different efficacy data for maintenance and this is more pronounced in the postsurgical setting. In this review article, the up-to-date Cochrane reviews on the topic are presented, including a network meta-analysis. The Cochrane evidence shows a high relapse rate in the first 5 years after surgery with placebo or no treatment...
May 2024: Frontline Gastroenterology
#4
JOURNAL ARTICLE
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
BACKGROUND: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents. OBJECTIVES: To provide real-world data in unselected patients with Crohn's disease (CD), treated with ustekinumab. DESIGN: Longitudinal retrospective study at four hospitals in Stockholm, Sweden. METHODS: Disease activity (Harvey-Bradshaw index and physician global assessment), laboratory parameters, endoscopic findings and drug persistence were assessed...
2024: Therapeutic Advances in Gastroenterology
#5
JOURNAL ARTICLE
Daniel L Hertz, Chad A Bousman, Howard L McLeod, Andrew A Monte, Deepak Voora, Lori A Orlando, Rustin D Crutchley, Benjamin Brown, Wrenda Teeple, Sara Rogers, Jai N Patel
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment...
April 23, 2024: American Journal of Health-system Pharmacy: AJHP
#6
Jacob C Massey, Joseph Magagnoli, S Scott Sutton, Phillip J Buckhaults, Michael D Wyatt
Genome instability is a hallmark of cancer and are driven by mutations in oncogenes and tumor suppressor genes. Despite successes seen with select targeted therapeutics, this type of personalized medicine is only beneficial for a small subpopulation of cancer patients who have one of a few actionable genetic changes. Most tumors also contain hundreds of passenger mutations that offered no fitness advantage or disadvantage during tumor evolution. Mutations in known pharmacogenetic (PGx) loci for which germline variants encode variability in drug response can cause somatically acquired drug sensitivity...
April 11, 2024: bioRxiv
#7
JOURNAL ARTICLE
Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Rebecca Smith, Christopher Roberts, Maria Bishara, Rachel Nice, Charlie W Lees, Shaji Sebastian, Peter M Irving, Richard K Russell, Timothy J McDonald, James R Goodhand, Tariq Ahmad, Nicholas A Kennedy
BACKGROUND: We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. METHODS: Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn's disease aged 6 years and older...
April 16, 2024: Lancet. Gastroenterology & Hepatology
#8
Sareena Ali, Meghana Doniparthi, Nahren Asado, Kristina Borgen, Alan Shapiro
There is a known association between inflammatory bowel disease (IBD) and vasculitis, which can present with mesenteric ischemia or cutaneous manifestations. Infliximab, an anti-tumor necrosis factor (anti-TNF) used to treat IBD, has been implicated as a potential culprit. We present a unique case of a patient with ulcerative colitis who developed isolated celiac artery vasculitis presenting with abdominal pain and ileus after decreasing his dosage of azathioprine. Vasculitis resolved with steroids and increasing azathioprine dosage, while continuing anti-TNF therapy, suggesting that anti-TNF agents are not the only cause of vasculitis in patients with IBD or that thiopurines may be protective...
April 2024: ACG Case Reports Journal
#9
JOURNAL ARTICLE
Noor Ali, Rafid Abdulkareem
BACKGROUND: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), exerts its impact on both rectal and colonic mucosa, with a growing incidence. This study aims to explore the pharmacogenetic influence of thiopurine methyl transferase (TPMT) gene expression and serum tumor necrosis factor (TNF) levels on the response to Imuran in Iraqi patients with UC. METHODS: Seventy individuals with chronic UC and 30 healthy controls were enrolled in this investigation...
October 2023: Reports of Biochemistry & Molecular Biology
#10
Ting Yang, Kang Chao, Xia Zhu, Xue-Ding Wang, Sumyuet Chan, Yan-Ping Guan, Jing Mao, Pan Li, Shao-Xing Guan, Wen Xie, Xiang Gao, Min Huang
BACKGROUND: Thiopurine-induced leucopenia significantly hinders the wide application of thiopurines. Dose optimization guided by nudix hydrolase 15 ( NUDT15 ) has significantly reduced the early leucopenia rate, but there are no definitive biomarkers for late risk leucopenia prediction. AIM: To determine the predictive value of early monitoring of DNA-thioguanine (DNATG) or 6-thioguanine nucleotides (6TGN) for late leucopenia under a NUDT15 -guided thiopurine dosing strategy in patients with Crohn's disease (CD)...
March 28, 2024: World Journal of Gastroenterology: WJG
#11
REVIEW
David M Mueller, Daniel I Nathan, Angela Liu, John Mascarenhas, Bridget K Marcellino
Patients with inflammatory bowel disease (IBD) are exposed to chronic systemic inflammation and are at risk for secondary malignancies. Here we review the literature on the risk of myeloid neoplasms (MN) in IBD and present the disease profiles of patients at a single institution with IBD who later developed MN, comparing them to those in the literature. No IBD characteristic was found to associate with MN disease severity, including the previously-identified association between MNs and thiopurine exposure. Of the somatic mutations identified in out cohort's MN, mutations in TET2 were most prevalent, followed by FLT3-ITD, BCR-ABL , and NPM1 mutations...
2024: Leukemia Research Reports
#12
JOURNAL ARTICLE
Yukako Nemoto, Shinya Tajima, Kota Saito, Arata Satoi, Takashi Matsui, Sei Kimura, Fumihiko Nakamura
Pouchitis is the most common long-term complication following ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis. Although several agents, including probiotics, steroids, and immunomodulators, have been used, the treatment of pouchitis remains challenging. Owing to the proven efficacy of biological therapy in inflammatory bowel disease, there is now growing evidence suggesting the potential benefits of biological therapy in refractory pouchitis. Here, we report the case of a 64-year-old woman with pouchitis due to ulcerative colitis who was successfully treated with ustekinumab (UST)...
2024: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
#13
JOURNAL ARTICLE
Motoki Makuuchi, Yoichi Kakuta, Junji Umeno, Toshimitsu Fujii, Tetsuya Takagawa, Takashi Ibuka, Miki Miura, Yu Sasaki, Sakuma Takahashi, Hiroshi Nakase, Hiroki Kiyohara, Keiichi Tominaga, Yosuke Shimodaira, Sakiko Hiraoka, Nobuhiro Ueno, Shunichi Yanai, Takeo Yoshihara, Kazuki Kakimoto, Katsuyoshi Matsuoka, Ryohei Hayashi, Sohachi Nanjo, Itaru Iwama, Yoh Ishiguro, Hirofumi Chiba, Katsuya Endo, Takashi Kagaya, Tomohiro Fukuda, Yasuhisa Sakata, Takahiro Kudo, Tomohisa Takagi, Kenichi Takahashi, Makoto Naganuma, Masaru Shinozaki, Noriyuki Ogata, Hiroki Tanaka, Kazuyuki Narimatsu, Haruka Miyazaki, Takashi Ishige, Motoyuki Onodera, Yu Hashimoto, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Hisashi Shiga, Yoshitaka Kinouchi, Akira Andoh, Tadakazu Hisamatsu, Atsushi Masamune
BACKGROUND: This study evaluated the effectiveness of NUDT15 codon 139 genotyping in optimizing thiopurine treatment for inflammatory bowel disease (IBD) in Japan, using real-world data, and aimed to establish genotype-based treatment strategies. METHODS: A retrospective analysis of 4628 IBD patients who underwent NUDT15 codon 139 genotyping was conducted. This study assessed the purpose of the genotyping test and subsequent prescriptions following the obtained results...
April 8, 2024: Journal of Gastroenterology
#14
JOURNAL ARTICLE
Michał Łodyga, Katarzyna Maciejewska, Kamila Stawczyk-Eder, Piotr Eder, Agnieszka Dobrowolska, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Małgorzata Cicha, Grażyna Rydzewska
INTRODUCTION: Although the phenomenon of cytokine storm is well described in patients with severe COVID-19, little is known about the role of the immune system in asymptomatic patients, especially in the group with autoimmune diseases, such as inflammatory bowel disease (IBD). AIM: To assess the stimulation of the immune system expressed through the production of cytokines in IBD patients with asymptomatic COVID-19. MATERIAL AND METHODS: This is a multi-centre, prospective study in which the concentration of many cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL- 15, IL-17, IL-23, IFN-γ, TNF-α, TNF-β) was assessed in patients with IBD and asymptomatic SARS-CoV-2 infection diagnosed by serological tests...
2024: Przegla̜d Gastroenterologiczny
#15
JOURNAL ARTICLE
Jaime E Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, Adrián Munilla-Das, Antonio Valdivia-Pérez, Francisco Javier Carrera-Hueso
BACKGROUND: Adalimumab biosimilar MSB11022 (Idacio ®) has been approved for the same indications as its originator (Humira ®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce. METHODS: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, 5 were directly started on MSB11022, and 9 switched from originator to biosimilar adalimumab...
April 2, 2024: Farmacia Hospitalaria
#16
JOURNAL ARTICLE
Manuel B Braga-Neto, Jason Nasser, Xiao Xing Iris Wang, William Scott Harmsen, Laura E Raffals, Michael Camilleri, Victor Chedid
INTRODUCTION: The aim of this case-control study was to determine if exposure to tumor necrosis factor alpha inhibitors (TNFIs) or immunomodulators (thiopurines or methotrexate) was associated with development of primary gastrointestinal lymphoma (PGIL) in patients with chronic inflammatory conditions. METHODS: Patients with PGIL and controls evaluated at a tertiary care center over 20 years were matched 1:3 using a medical record informatics search engine based on their chronic inflammatory condition (Crohn's disease [CD], ulcerative colitis [UC], rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and duration of follow-up...
January 2024: Crohn's & colitis 360
#17
REVIEW
Piyush Mahajan, Mahesh Palkar, Ravindra Babu Pingili
Nowadays, drug-induced liver toxicity (DILT) is one of the main contributing factors to severe liver disease. In the United States (US) alone, DILT is the cause of more than 50% of instances of acute liver failure. Prescription or over-the-counter drugs, xenobiotics, and herbal and nutritional supplements can cause DILT and could produce anomalies in hepatic function tests. Some drugs induce hepatotoxicity directly, and others induce it indirectly (i. e. through their toxic or reactive metabolites). Currently, the United States Food and Drug Administration (US FDA) has issued black box warnings to about 1279 drugs due to their hepatotoxicity...
March 19, 2024: Toxicology Mechanisms and Methods
#18
Sydney Smith, Daniel Grove
Toxic erythema of chemotherapy is a broad but useful diagnosis used to summate the non-infectious, non-allergic, and reproducible reaction of certain chemotherapeutics. Due to overlapping chemotherapy side effects and often multiple drug exposures, identification of a singular culprit drug is challenging for dermatologists. Herein, we report a patient with 6-mercaptopurine (6-MP) toxic erythema confirmed via toxic metabolite markers secondary to increased levels of thiopurine methyltransferase activity, or so called "super shunting...
March 13, 2024: Pediatric Dermatology
#19
JOURNAL ARTICLE
Chuang-Hsin Chiu, David J Yang, Yi-Chen Liou, Wei-Chung Chang, Tsung-Hsun Yu, Min-Ching Chung, Yen-Chun Lee, Ing-Jou Chen, Pao-Yeh Wang, Ching-Po Lin, Hey-Jen Tsay, Skye Hsin-Hsien Yeh
Background: DNA biomarkers are useful for the assessment of tumor cell proliferation. The authors aimed to synthesize a thiopurine-based ligand for evaluation of nuclear uptake and tumor localization. Materials and Methods: A 2-hydroxypropyl spacer was incorporated between a chelator (cyclam) and thiopurine ligand to produce SC-06-L1. In vitro cellular uptake and the cell/media ratios of [99m Tc]Tc-SC-06-L1 were assessed in breast (MCF-7, MDA-MB-231) and ovarian (TOV-112D, OVCAR3) cancer cells. The nuclear and cytosolic uptake ratio of [99m Tc]Tc-SC-06-L1 was determined in OVCAR-3 and MCF-7 cells...
March 8, 2024: Cancer Biotherapy & Radiopharmaceuticals
#20
JOURNAL ARTICLE
Ivan Guerra, Francisco Barros, María Chaparro, José M Benítez, María Dolores Martín-Arranz, Ruth de Francisco, Marta Piqueras, Luisa de Castro, Ana Y Carbajo, Fernando Bermejo, Miguel Mínguez, Ana Gutiérrez, Francisco Mesonero, Fiorella Cañete, Carlos González-Muñoza, Marta Calvo, Beatriz Sicilia, Erika Alfambra, Montserrat Rivero, Alfredo J Lucendo, Carlos A Tardillo, Pedro Almela, Luis Bujanda, Manuel van Domselaar, Laura Ramos, María Fernández Sánchez, Esther Hinojosa, Cristina Verdejo, Anna Gimenez, Iago Rodríguez-Lago, Noemí Manceñido, José L Pérez Calle, Mónica Del Pilar Moreno, Pedro Genaro Delgado-Guillena, Beatriz Antolín, Patricia Ramírez de la Piscina, María José Casanova, Pilar Soto Escribano, Eduardo Martín Arranz, Isabel Pérez-Martínez, Raquel Mena, Natalia García Morales, Alicia Granja, Marta Maia Boscá Watts, Rubén Francés, Cristina Fernández, Margalida Calafat, Cristina Roig-Ramos, María Isabel Vera, Ángel Carracedo, Eugeni Domènech, Javier P Gisbert
BACKGROUND: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. AIM: Our aim was to evaluate the predictive pharmacogenetic risk of pancreatitis in IBD patients treated with thiopurines. METHODS: We conducted an observational pharmacogenetic study of acute pancreatitis events in a cohort study of IBD patients treated with thiopurines from the prospectively maintained ENEIDA registry biobank of GETECCU...
March 7, 2024: Digestive Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
